Drug updated on 3/28/2024
| Dosage Form | Tablet (oral; 20 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.
Summary
- Cobimetinib (Cotellic) is used for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, often in combination with vemurafenib.
- A network meta-analysis study found that encorafenib + binimetinib was superior to cobimetinib (Cotellic) + vemurafenib in terms of overall response rate and had fewer serious adverse events and discontinuations due to adverse events.
- Another systematic review indicated that the acceptability of combined dabrafenib and trametinb was superior to the combination of cobimetinb (Cotellic) and vemurafenab when considering any-grade adverse events.
- In comparison with immunotherapies, results varied for progression-free survival and overall survival according to one literature review which suggested that long-term survival data establishes dabrafenb + trametnimb as one preferred treatment option over cobimtenb (Cotellic).
- The information above is derived from eight Systematic Reviews / Meta-Analyses documents focusing on comparing different treatments including Cobimtenb (Cotellic), particularly their efficacy, safety profile, patient acceptability based on side effects among others.
- It's important for health professionals prescribing this drug to consider these findings about its comparative effectiveness against other drugs like encorafanbib+binmetnimb or dabrafnibr+tramtnmb especially regarding patient outcomes such as progression-free survival rates, overall response rates along side potential severe adversities associated with each regimen.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Cotellic (cobimetinib) Prescribing Information. | 2022 | Genentech USA, Inc., South San Francisco, CA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Systemic therapy for melanoma: ASCO guideline. | 2020 | Journal of Clinical Oncology |